C
ancer ste
m cells (CSCs)
are thought to be persistent in tu
mours
due to their che
moresist
ance
an
d to c
ause rel
apse
an
d met
ast
asis. Hep
atic c
arcino
mas
displ
aying hep
atic progenitor cell (HPC)
fe
atures h
ave been
associ
ate
d with
a poor prognosis, though it re
mains uncle
ar how CSCs rel
ate to these
di
fferent histologic
al subtypes.
d="absSec_2">Methods
d="sp0015">Candidate CSCs were isolated using the side population (SP) technique from primary tissue samples diagnosed as keratin(K)19-negative or -positive hepatocellular carcinoma (HCC) or as combined hepatocellular/cholangiocarcinoma and analysed for gene and protein expression. The effect of laminin-332 was analysed m>in vitrom> by using HCC cell lines and m>in vivom> using a xenograft mouse model.
d="absSec_3">Results
d="sp0020">The size of the SP correlated with the degree of HPC features found in human hepatic cancer, and also showed an elevated mRNA expression of biliary/HPC markers and the extracellular matrix marker m>LAMC2m>, the gene encoding the laminin γ2-chain. Immunopositivity for the γ2-chain of laminin-332 was seen in the extracellular matrix surrounding small HPC-like tumour cells with a low proliferation rate. m>In vitrom>, laminin-332 increased K19 expression, phosphorylated mTOR and decreased phospho-histone H3 expression, indicating reduced cell mitosis. The effect of laminin-332 was enhanced upon mTORC1 inhibition and diminished when inhibiting mTORC1+C2. Resistance to doxorubicin and sorafenib treatment, and the SP fraction increased in the coated condition. m>In vivom>, laminin-332 reduced tumour growth and sustained K19 expression.
d="absSec_4">Conclusions
d="sp0025">In this study we identified a prominent role for laminin-332 as part of the specialised CSC niche in maintaining and supporting cell ‘stemness’, which leads to chemoresistance and quiescence.